UBS Upgrades Chimera Investment to Buy, Raises Price Target to $15
Benzinga Newsdesk 1 year ago
NewsUpgradesPrice TargetAnalyst Ratings
UBS analyst Douglas Harter upgrades Chimera Investment (NYSE:CIM) from Neutral to Buy and raises the price target from $11.5 to $15.
UBS analyst Douglas Harter upgrades Chimera Investment (NYSE:CIM) from Neutral to Buy and raises the price target from $11.5 to $15.